Published on : Mar 11, 2015
BMG Pharma S.r.l., a specialty pharmaceutical firm, has made an announcement that it will launch its proprietary product Ialuxid gel in the People’s Republic of China.
The Chinese version of the Ialuxid gel will be a non-antibiotic antimicrobial gel that retains the moist wound environment that promotes quicker healing. Ialuxid is especially useful for post surgical wounds. Luqa Pharmaceuticals, after receiving the approval for Ialuxid gel in China, will initiate rolling out of the gel across the country through its national coverage.
Marco Mastrodonato, the CEO of BMG Pharma, said that since the beginning of our cooperation for Ialuxid gel in China in May 2013, Luqa has worked in earnest to set the product’s distribution going in a record pace. He said the company is pleased to offer Ialuxid gel to new patients in China’s healthcare organizations. They will receive the best care possible through the company’s innovative delivery technology which provides quick relief to skin infections.
He added that the long term partnership will be a significant benchmark for BMG Pharma, which is opening its doors to the most dynamic and exciting healthcare market in the world.
CEO of Luqa Pharmaceuticals, Robert Braithwaite, said that the Ialuxid gel’s Chinese launch will represent a milestone for his company. The gel is an outstanding addition to our portfolio of skin solutions that focus on enhancing a patient’s overall quality of life. He said that he was thankful for the support provided by BMG and hopes that the long term collaboration will allow us to bring the rest of their top drugs to the China market.
Ialuxid gel is registered in Europe as a treatment for acne lesions, Molluscum Contagiosum, paronychia, folliculitis, and impetigo.